Relay Therapeutics (RLAY) Leases (2020 - 2025)
Relay Therapeutics (RLAY) has disclosed Leases for 6 consecutive years, with $40.0 million as the latest value for Q4 2025.
- On a quarterly basis, Leases fell 22.74% to $40.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $40.0 million, a 22.74% decrease, with the full-year FY2025 number at $40.0 million, down 22.74% from a year prior.
- Leases was $40.0 million for Q4 2025 at Relay Therapeutics, down from $41.4 million in the prior quarter.
- In the past five years, Leases ranged from a high of $65.2 million in Q3 2022 to a low of $19.8 million in Q2 2022.
- A 5-year average of $45.5 million and a median of $51.8 million in 2024 define the central range for Leases.
- Peak YoY movement for Leases: soared 207.2% in 2023, then fell 22.74% in 2025.
- Relay Therapeutics' Leases stood at $20.8 million in 2021, then soared by 206.8% to $63.8 million in 2022, then fell by 9.07% to $58.0 million in 2023, then fell by 10.71% to $51.8 million in 2024, then dropped by 22.74% to $40.0 million in 2025.
- Per Business Quant, the three most recent readings for RLAY's Leases are $40.0 million (Q4 2025), $41.4 million (Q3 2025), and $42.7 million (Q2 2025).